series-a
Stage
2020
Founded
1
Investors
About
Leucid Bio develops next-generation CAR-T cell therapies using a proprietary Lateral CAR platform aimed at treating refractory cancers by enhancing T-cell potency and reducing toxicity.
Explore Leucid Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.